PTLA Portola Pharmaceuticals Inc.

28.35
+0.02  (+0%)
Previous Close 28.33
Open 28.34
Price To Book 10.35
Market Cap 2,206,173,073
Shares 77,819,156
Volume 655,684
Short Ratio
Av. Daily Volume 744,088
Stock charts supplied by TradingView

NewsSee all news

  1. Andexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency Physicians

    SOUTH SAN FRANCISCO, Calif., Nov. 15, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that Annals of Emergency Medicine, the journal of the American College of Emergency Physicians

  2. Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting

    SOUTH SAN FRANCISCO, Calif., Nov. 6, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an

  3. Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    SOUTH SAN FRANCISCO, Calif., Nov. 5, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today reported financial results for the three months ended September 30, 2019, and provided a corporate update.

  4. Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Nov. 1, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on October 31, 2019, the Compensation Committee of the Board of Directors approved, effective as

  5. Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019

    SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval noted June 23, 2017.
Bevyxxa (betrixaban)
Venous thromboembolism (VTE) Prevention
Phase 2a interim data to be presented at ASH December 8, 2019, at 12:45 p.m. EST.
Cerdulatinib (PRT2070)
Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer
Prior Approval Supplement (PAS) FDA Approval announced December 31, 2018.
Andexxa
Factor Xa inhibitor reversal agent

Latest News

  1. Andexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency Physicians

    SOUTH SAN FRANCISCO, Calif., Nov. 15, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that Annals of Emergency Medicine, the journal of the American College of Emergency Physicians

  2. Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting

    SOUTH SAN FRANCISCO, Calif., Nov. 6, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an

  3. Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    SOUTH SAN FRANCISCO, Calif., Nov. 5, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today reported financial results for the three months ended September 30, 2019, and provided a corporate update.

  4. Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Nov. 1, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on October 31, 2019, the Compensation Committee of the Board of Directors approved, effective as

  5. Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019

    SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for

  6. Portola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Sept. 19, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the appointment of Ted W. Love, M.D., to its Board of Directors. Dr. Love is a recognized industry

  7. Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 22, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that the Company will participate in the following conferences in September. Citi's 14th Annual